12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Singular Genomics Sys (NASDAQ:OMIC) shares moved upwards by 17.9% to $0.66 during Friday’s after-market session. The market…
Singular Genomics Showcases New G4X Spatial Sequencer At AGBT And Announces Significant Advances In Throughput, Quality, And Usability For G4 Sequencing Platform
Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced groundbreaking new products
Singular Genomics Reports Instrument Shipments And Preliminary Unaudited Q4 2023 Revenue; Sees Q4 Revenue Of $1M Vs $765K YoY
Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and
Recap: Singular Genomics Sys Q3 Earnings
Singular Genomics Sys (NASDAQ:OMIC) reported its Q3 earnings results on Tuesday, November 14, 2023 at 04:01 PM. Here’s…
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell
• CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million.
Why INVO Bioscience Shares Are Trading Higher By Over 31%; Here Are 20 Stocks Moving Premarket
INVO Bioscience, Inc. (NASDAQ: INVO) shares surged in pre-market trading after the company posted a narrower loss for the third quarter.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Tivic Health Systems (NASDAQ:TIVC) shares rose 116.8% to $2.58 during Monday’s pre-market session. The company’s market cap…
12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers INVO Bioscience (NASDAQ:INVO) stock increased by 115.4% to $1.48 during Friday’s regular session. As of 12:31 EST,…
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
